Novel Toxoplasma gondii inhibitor chemotypes

A. G. Sanford, T. T. Schulze, L. P. Potluri, R. M. Hemsley, J. J. Larson, A. K. Judge, S. J. Zach, X. Wang, S. A. Charman, Jonathan L Vennerstrom, Paul H Davis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC50 values ranging from 0.3 to 2 μM, comparable to that of 0.25 to 1.5 μM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD7.4 and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5 mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.

Original languageEnglish (US)
Pages (from-to)107-111
Number of pages5
JournalParasitology International
Volume67
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Toxoplasma
Pyrans
Cell Line
Hydrazones
Pyrimethamine
Drug and Narcotic Control
Antimalarials
Solubility
Inhibitory Concentration 50
Growth

Keywords

  • Anti-parasitics
  • Drug discovery
  • Lead compounds
  • Plasmodium falciparum
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Sanford, A. G., Schulze, T. T., Potluri, L. P., Hemsley, R. M., Larson, J. J., Judge, A. K., ... Davis, P. H. (2018). Novel Toxoplasma gondii inhibitor chemotypes. Parasitology International, 67(2), 107-111. https://doi.org/10.1016/j.parint.2017.10.010

Novel Toxoplasma gondii inhibitor chemotypes. / Sanford, A. G.; Schulze, T. T.; Potluri, L. P.; Hemsley, R. M.; Larson, J. J.; Judge, A. K.; Zach, S. J.; Wang, X.; Charman, S. A.; Vennerstrom, Jonathan L; Davis, Paul H.

In: Parasitology International, Vol. 67, No. 2, 01.04.2018, p. 107-111.

Research output: Contribution to journalArticle

Sanford, AG, Schulze, TT, Potluri, LP, Hemsley, RM, Larson, JJ, Judge, AK, Zach, SJ, Wang, X, Charman, SA, Vennerstrom, JL & Davis, PH 2018, 'Novel Toxoplasma gondii inhibitor chemotypes', Parasitology International, vol. 67, no. 2, pp. 107-111. https://doi.org/10.1016/j.parint.2017.10.010
Sanford AG, Schulze TT, Potluri LP, Hemsley RM, Larson JJ, Judge AK et al. Novel Toxoplasma gondii inhibitor chemotypes. Parasitology International. 2018 Apr 1;67(2):107-111. https://doi.org/10.1016/j.parint.2017.10.010
Sanford, A. G. ; Schulze, T. T. ; Potluri, L. P. ; Hemsley, R. M. ; Larson, J. J. ; Judge, A. K. ; Zach, S. J. ; Wang, X. ; Charman, S. A. ; Vennerstrom, Jonathan L ; Davis, Paul H. / Novel Toxoplasma gondii inhibitor chemotypes. In: Parasitology International. 2018 ; Vol. 67, No. 2. pp. 107-111.
@article{d349b30b81324a0ca76c4ef23307cae1,
title = "Novel Toxoplasma gondii inhibitor chemotypes",
abstract = "We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC50 values ranging from 0.3 to 2 μM, comparable to that of 0.25 to 1.5 μM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD7.4 and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5 mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.",
keywords = "Anti-parasitics, Drug discovery, Lead compounds, Plasmodium falciparum, Toxoplasma gondii",
author = "Sanford, {A. G.} and Schulze, {T. T.} and Potluri, {L. P.} and Hemsley, {R. M.} and Larson, {J. J.} and Judge, {A. K.} and Zach, {S. J.} and X. Wang and Charman, {S. A.} and Vennerstrom, {Jonathan L} and Davis, {Paul H}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.parint.2017.10.010",
language = "English (US)",
volume = "67",
pages = "107--111",
journal = "Parasitology International",
issn = "1383-5769",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Novel Toxoplasma gondii inhibitor chemotypes

AU - Sanford, A. G.

AU - Schulze, T. T.

AU - Potluri, L. P.

AU - Hemsley, R. M.

AU - Larson, J. J.

AU - Judge, A. K.

AU - Zach, S. J.

AU - Wang, X.

AU - Charman, S. A.

AU - Vennerstrom, Jonathan L

AU - Davis, Paul H

PY - 2018/4/1

Y1 - 2018/4/1

N2 - We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC50 values ranging from 0.3 to 2 μM, comparable to that of 0.25 to 1.5 μM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD7.4 and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5 mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.

AB - We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC50 values ranging from 0.3 to 2 μM, comparable to that of 0.25 to 1.5 μM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD7.4 and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5 mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.

KW - Anti-parasitics

KW - Drug discovery

KW - Lead compounds

KW - Plasmodium falciparum

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=85034438632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034438632&partnerID=8YFLogxK

U2 - 10.1016/j.parint.2017.10.010

DO - 10.1016/j.parint.2017.10.010

M3 - Article

VL - 67

SP - 107

EP - 111

JO - Parasitology International

JF - Parasitology International

SN - 1383-5769

IS - 2

ER -